SEOUL -- South Korean biopharmaceutical company Samsung Biologics plans to focus exclusively on its contract drug manufacturing business, with three new factories to be built by 2032.
Biotechnology
Samsung Biologics pivots to contract drugmaking, eyeing $40bn market
South Korean firm to shed in-house development arm, then add 3 plants by 2032
Samsung Biologics landed a record-breaking contract drug manufacturing deal this year. (Samsung Biologics)
Read Next
Latest on Biotechnology
